GlassScriptPhysician profile
Amanda Lynn Keith
NPI 1689034514
$3,117.00
in general payments reported to CMS, 2019-2025
36 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $244 · 2023: $294 · 2024: $1,014 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.05 | 2021-2025 | |
| Novo Nordisk INC | $478.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $201.74 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.78 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $146.91 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $140.61 | 2022-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $102.10 | 2025 | Qelbree |
| Amgen INC. | $93.21 | 2023-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $90.78 | 2024-2025 | Airsupra |
| Alkermes, INC. | $82.63 | 2024-2025 | Vivitrol |
| Lundbeck LLC | $78.48 | 2024-2025 | Rexulti |
| Esperion Therapeutics, INC. | $69.61 | 2025 | Nexletol |
| Aimmune Therapeutics, INC. | $62.42 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.31 | 2024-2025 | Xifaxan |
| Astellas Pharma US INC | $59.83 | 2023-2025 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.90 | 2021-2024 | Gardasil, Gardasil 9 |
| Corcept Therapeutics | $48.44 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $40.12 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $39.02 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $33.77 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Baxter Healthcare | $32.83 | 2025 | Perclot |
| Phathom Pharmaceuticals, INC. | $32.68 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $30.59 | 2022 | |
| Medtronic, INC. | $29.02 | 2025 | Synchromedii |
| Axonics, INC. | $26.08 | 2022 | |
| Neurocrine Biosciences, INC. | $25.89 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $25.18 | 2024 | Fanapt, Hetlioz |
| Corium, LLC | $24.17 | 2024 | Azstarys |
| Advanced Oxygen Therapy INC. | $22.66 | 2025 | Topical Oxygen Chamber For Extremities |
| Dexcom, INC. | $22.22 | 2024 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $20.51 | 2025 | Isturisa |
| Nestle Healthcare Nutrition INC. | $18.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.81 | 2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $16.16 | 2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $15.48 | 2024 | Quviviq |
| Smith+Nephew, INC. | $14.25 | 2025 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.